期刊文献+

ACS患者脂蛋白相关磷脂酶A_2及CD4^+干扰素-γ阳性细胞与TIMI血流的关系 被引量:2

Correlation between lipoprotein-associated phospholipase A_2,CD4^+ IFN-γ^+ positive cells and coronary TIMI blood flow in patients with acute coronary syndrome
下载PDF
导出
摘要 目的探讨急性冠状动脉综合征(acute coronary syndromes,ACS)患者脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,LP-PLA2)、CD4+干扰素γ+(interferon-γ,IFN-γ+)细胞表达与经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗中心肌梗死溶栓(thrombolysis in myocardial infarction,TIMI)血流的关系。方法选择接受PCI治疗的ACS患者993例为研究对象。所有患者经冠状动脉造影确诊及行PCI治疗,根据TIMI血流0~Ⅲ级分为A、B、C、D共4个亚组;同期选择非冠状动脉粥样硬化性心脏病(冠心病)体检者580名为对照组。患者发病后24h内采用流式细胞仪检测CD4+IFN-γ+双阳性细胞比例,酶联免疫吸附法检测血清Lp-PLA2浓度。多元回归法分析TIMI血流与血清Lp-PLA2浓度、CD4+IFN-γ+双阳性细胞的比例的关系。结果 ACS患者起病24h内的血清Lp-PLA2浓度、CD4+IFN-γ+比例显著高于对照组比较,差异有统计学意义[(328.2±8.2)μg/L vs.(100.6±11.3)μg/L,P<0.05;32.6%±5.8%vs.8.8%±3.2%,P<0.05]。方差分析显示,A、B、C、D4个亚组PCI治疗后血清Lp-PLA2浓度、CD4+IFN-γ+双阳性细胞的比例比较,差异有统计学意义(P<0.05),且A、B组高于C、D组,差异有统计学意义(P<0.05)。多元回归分析显示,TIMI血流与血清Lp-PLA2浓度、CD4+IFN-γ+双阳性细胞的比例呈正相关(r=-0.693,P<0.05;r=-0.584,P<0.05)。结论检测血清Lp-PLA2浓度、CD4+IFN-γ+细胞比例对斑块的不稳定性评价及预测PCI治疗中的无再流或慢血流现象有重要意义。 Objectives To observe the correlation between lipoprotein-associated phospholipase A2(LP-PLA2),CD4^+ interferon (IFN)-γ^+ positive cells and coronary thrombolysis in myocardial infarction (TIMI) blood flow in patients with acute coronary syndromes (ACS). Methods We selected 993 patients with ACS as objects (ACS group)and 580 persons examinated without coronary disease as controls (control group). All the patients were conducted percutaneous coronary interventions (PCI) and divided into A, B, C, D groups by TIMI blood flow. Peripharal blood samples were collected within 24 h. CD4+ IFN-y^+ positive cell levels were detected with flow cytometry (FCM), serum concentration of Lp-PLA2 was detected by enzyme-linked immunosorbent assay (ELISA). Results Serum concentration of Lp-PLA2 and CD4^+IFN-γ^+ positive cells levels of ACS group were significantly higher than those in control group [ (328.2±8.2) μg/L vs. (100.6±11.3)μg/L,P〈0.05;32.6%±5.8% vs.8.8%±3.2% ,P〈0.05]. Analysis of variance indicated that serum concentration of Lp-PLA2 and CD4^+ IFN-γ^+ positive cell levels of A, B, C, D group were significantly difference (P〈0.05). Moreover, serum concentration of Lp-PLA2 and CD4^+ IFN-γ^+ positive cell levels of A, B group were significantly higher than those in C, D group (P〈0.05). Multiple regression analysis indicated that TIMI blood flow was positive correlated with serum concentration of Lp-PLA2 and CD4^+ IFN-γ^+ positive cell levels (r=-0.693 ,P〈0.05 ;r=-0.584,P〈0.05). Conclusions Serum concentration of Lp-PLA2 and CD4^+ IFN-γ^+ positive cell level may be good predictive factors for unstable plaque of ACS, and could be used to prognosticate of slow-flow or non-flow after PCI.
出处 《岭南心血管病杂志》 2010年第5期364-367,共4页 South China Journal of Cardiovascular Diseases
关键词 冠状动脉疾病 血管成形术 经腔 经皮冠状动脉 干扰素Γ 脂蛋白相关磷脂酶A2 coronary artery disease percutaneous coronary interventions interferon-γ lipoprotein-associated phospholipase A2
  • 相关文献

参考文献13

  • 1CORSETTI J P,RA I NWATER D L,MOSS A J,et al. High lipoprotein-associated phos pholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J]. Clin Chem, 2006,52(7) : 1331-1338.
  • 2BR I LAKIS E S,MCCONNELL J P,LENNON R J,et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow up [J]. Eur Heart J,2005,26 (2) : 1372-1441.
  • 3HANSSON G K,NILSSON J. Introduction : atberosclerosis as inflammation : a controversial concept becomes accepted [J ]. J Intern Med, 2008,263 (5) : 462-463.
  • 4高润霖,刘冰.经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2002,30(12):707-718. 被引量:336
  • 5LAVI S, MCCONNELL J P, RIHAL C S, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidyl- choline in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans [ J ]. Cireulation, 2007,115 ( 21 ) : 2715-2721.
  • 6KOLODGIE F D,BURKE A P,SKORIJA K S,et al. Lipoproteinassoeiated phospholipase A2 protein expression in the natural progression of human coronary atheroselerosis [ J ]. Arterioseler Thromb Vasc Biol, 2006,26( 11 ) : 2523- 2529.
  • 7ZALEWSKI A,MACPHEE C. Role of lipoprotein associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target [ J ]. Arterioscler Thromb Vasc Biol, 2005,25(5) : [7] 923- 931.
  • 8TSIM1KAS S,WILL EIT J,KNOFLACH M, et al. Lipoprotein- associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality : results from the Bruneck study [J]. Eur Heart J, 2009, 30( 1 ) : 107-115.
  • 9BRILAKIS E S,MCCONNELL J P,LENNON R J,et al. Association of lipopmtein associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow up[J]. Eur Heart J, 2005,26 ( 2 ) : 137-144.
  • 10陶荣,廖玉华,程翔,胡燕,王敏,王朝晖.过继转输急性心肌梗死大鼠脾细胞介导心肌损伤[J].中国免疫学杂志,2003,19(9):642-644. 被引量:23

二级参考文献25

  • 1庞红,廖玉华,汪朝辉,董继华,吕清.Effect of Anti-Cardiac Myosin Antibody on Prognosis of Patients with Acute Myocardial Infarction[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2000,20(1):46-48. 被引量:11
  • 2陈晓春,周艳芳,葛智平.冠状动脉内支架置入术后血清白细胞介素6与白细胞介素10水平的变化[J].中国介入心脏病学杂志,2005,13(2):97-99. 被引量:7
  • 3冯宗忱.动脉粥样硬化——血管壁的慢性炎症[J].中华心血管病杂志,2005,33(5):393-394. 被引量:66
  • 4廖玉华,陶荣,程翔,童丹,胡燕,王敏,王朝晖.急性心肌梗死后心肌炎症反应及其意义[J].中国分子心脏病学杂志,2002,2(3):7-10. 被引量:40
  • 5Erglis A,Kumsars I,Niemela M,et al.Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents:the Nordic stent technique study.Circ Cardiovasc Interv.2009;2(1):27-34.
  • 6Reddy MK,Vasir JK,Sahoo SK,et al.Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery.Circ Cardiovasc Interv.2008;1(3):209-216.
  • 7Jensen LO,Maeng M,Thayssen P,et al.Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction.Circ Cardiovasc Interv.2008; 1(3):176-184.
  • 8Singhal A,Stokes K,Sebastian A,et al.Endovascular treatment of hepatic artery thrombosis following liver transplantation.Transpl Int.2009 Dec 22.[Epub ahead of print].
  • 9Canan T,Lee MS.Drug-eluting stent fracture:incidence,contributing factors,and clinical implications.Catheter Cardiovasc Interv.2010; 75(2):237-245.
  • 10Wilczynski M,Bochenek T,Goral J,et al.Bridging by eptifibatide on patients with acute stent thrombosis,requiring urgent surgical revascularisation-report of 2 cases.Kardiol Pol.2009;67(11):1313-1316.

共引文献362

同被引文献24

  • 1吴俊,周贤刚.阿乐(阿托伐他汀)治疗高脂血症的Meta分析[J].实用临床医学(江西),2006,7(12):41-46. 被引量:3
  • 2李乐,高小利,丁宝兴,袁秉祥.绞股蓝总黄酮对缺氧/复氧心肌细胞TNF-α浓度,Fas/FasL蛋白表达的影响[J].中国中药杂志,2007,32(18):1925-1927. 被引量:4
  • 3冯毅,王积慧,沈成兴,马根山.急性冠脉综合征氧化应激损伤及与低密度脂蛋白的相关性[J].心血管康复医学杂志,2007,16(5):452-455. 被引量:8
  • 4Tefferi A. Varidiman JW. Classification and diagnosis of myeloproliferative neoplasms : the 2008 World Health Organization criteria and point-of-care diagnostic algorithms [J].Leukemia, 2008,22( 1 ) : 14-22.
  • 5Bhagwat N, Levine RL, Koppikar P. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms [J]. International journal of hematology, 2013,97 (6) : 695-702.
  • 6Verstovsek S, Kanmr JH, Mesa RA, et al. Safety and efficacy of INCB018424,a JAKI and JAK2 inhibitor,in myelofibosis [J]. N Engl J Med,2010,363(12) : 1117-1127.
  • 7Dawson MA, Curry JE, Barber K, et al. AT9283,a potent inhibitor of the Aurora kinases and JAK2,has therapeutic potential in myeloproliferative disorder [J]. Br J Haematol, 2010,150(1) :46-57.
  • 8Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responseswith low toxicity inpolycythemiavera [J]. Blood, 2008,112 ( 8 ) : 3065 - 3072.
  • 9Quintas-Cardama, A, Abdel-Wahab OA, Manshouri et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a [J]. Blood,2013,122(6) :893-901.
  • 10Mullally A, Bruedigam C, Bruedigam C, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murlne model of polycythemia vera [J]. Blood, 2013,121 ( 18 ) : 3692-3702.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部